(P-344) Modeling Confirms Islatravir 0.25 mg Administered Daily Has No Adverse Effect on Total Lymphocyte or CD4+ T-cell Counts in People Living with HIV

Monday, October 20, 2025

12:15 PM - 1:30 PM US ET

Location: Poster Hall B4-B5

Presenting Author(s)

Brian M. Maas, PharmD (he/him/his)

Director
Merck & Co., Inc.
Rahway, NJ, United States

BP

Bill Poland, PhD

Certara
Princeton, New Jersey, United States
Michelle M. Pham, PhD (she/her/hers)

Senior Specialist
Merck & Co., Inc., United States
MJ

Martin Johnson, PhD

Allucent
Bracknell, England, United Kingdom
IB

Irene Bae, PharmD

Certara
Princeton, New Jersey, United States
SR

Seth H. Robey, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
BK

Bhargava Kandala, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
XZ

Xiaowei Zang, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
SK

Stephanie O. Klopfer, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
MF

Michelle C. Fox, MD

Merck & Co., Inc.
Rahway, New Jersey, United States
RV

Ryan C. Vargo, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States